STRATA Skin Sciences, Inc. (SSKN) |
1.73 -0.11 (-5.98%) 10-09 16:00 |
Open: | 1.82 |
High: | 1.9 |
Low: | 1.73 |
Volume: | 132,786 |
Market Cap: | 7(M) |
PE Ratio: | -0.61 |
Exchange: | NASDAQ Capital Market |
Industry: | Medical - Devices |
Sector: | Healthcare |
Technical analysis | ||||
![]() |
||||
sell | buy |
Resistance 2: | 3.04 |
Resistance 1: | 2.41 |
Pivot price: | 2.01 |
Support 1: | 1.38 |
Support 2: | 1.15 |
52w High: | 3.86 |
52w Low: | 1.38 |
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. Its products include XTRAC and Pharos excimer lasers, VTRAC lamp systems, and TheraClear treatment systems that are used for the treatment of psoriasis, vitiligo, acne, and other skin conditions. The company distributes its products internationally through distributors, and domestically directly to physicians. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.
EPS | -2.840 |
Book Value | 0.070 |
PEG Ratio | 0.00 |
Gross Profit | 3.603 |
Profit Margin (%) | -35.13 |
Operating Margin (%) | -29.02 |
Return on Assets (ttm) | -11.1 |
Return on Equity (ttm) | -235.4 |
Tue, 07 Oct 2025
STRATA Study Shows Excimer Laser Plus Tacrolimus Boosts Psoriasis Outcomes - MSN
Mon, 06 Oct 2025
STRATA Highlights Excimer Laser as Effective Option for Atopic Dermatitis - MyChesCo
Fri, 03 Oct 2025
STRATA Skin Sciences Highlights Efficacy of XTRAC® Excimer Laser in Treating Atopic Dermatitis During Eczema Awareness Month - Quiver Quantitative
Fri, 03 Oct 2025
Marking Eczema Awareness Month – Clinical Research Validates Strata Skin Sciences’ XTRAC® Excimer Laser as a Breakthrough Therapy for Localized Atopic Dermatitis - GlobeNewswire
Fri, 03 Oct 2025
16.5M Adults: STRATA's XTRAC® and AMA Indication Expansion Enables Reimbursement for Atopic Dermatitis - Stock Titan
Tue, 23 Sep 2025
STRATA Skin Sciences stock soars after promising vitiligo study results - Investing.com
![]() StockChart iOS |
![]() StoxlineLite iOS |
![]() StoxlineLite iOS |
![]() OptionCalc iOS |
![]() StockChart Android |
![]() StoxlineLite Android |
![]() StoxlinePro Android |
![]() OptionCalc Android |